Operating
Net Income
Alnylam Pharmaceuticals Net Income increased by 39.9% to $205.99M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1228.7%, from -$18.25M to $205.99M. Over 4 years (FY 2021 to FY 2025), Net Income shows an upward trend with a -22.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2014
Last reportedQ1 2026
How to read this metric
An increase indicates higher profitability and operational success, while a decrease may signal rising costs or declining sales.
Detailed definition
Net income represents the total profit of the company after all operating expenses, taxes, and interest have been deduct...
Peer comparison
Standard across all public companies, though margins vary significantly by industry sector.
Metric ID:
net_income_cfHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$189.56M | -$204.51M | -$258.46M | -$240.34M | -$277.40M | -$405.92M | -$207.49M | -$174.10M | -$276.02M | $147.75M | -$137.87M | -$65.94M | -$16.89M | -$111.57M | -$83.76M | -$18.25M | -$66.28M | $251.08M | $147.19M | $205.99M |
| QoQ Change | — | -7.9% | -26.4% | +7.0% | -15.4% | -46.3% | +48.9% | +16.1% | -58.5% | +153.5% | -193.3% | +52.2% | +74.4% | -560.6% | +24.9% | +78.2% | -263.1% | +478.8% | -41.4% | +39.9% |
| YoY Change | — | — | — | — | -46.3% | -98.5% | +19.7% | +27.6% | +0.5% | +136.4% | +33.6% | +62.1% | +93.9% | -175.5% | +39.2% | +72.3% | -292.4% | +325.0% | +275.7% | >999% |
Range-$405.92M – $251.08M
CAGR+1.8%
Avg YoY Growth+106.4%
Median YoY Growth+36.4%
Net Income at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's net income?
- Alnylam Pharmaceuticals (ALNY) reported net income of $205.99M in Q1 2026.
- How has Alnylam Pharmaceuticals's net income changed year-over-year?
- Alnylam Pharmaceuticals's net income increased by 1228.7% year-over-year, from -$18.25M to $205.99M.
- What is the long-term trend for Alnylam Pharmaceuticals's net income?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's net income has grown at a -22.1% compound annual growth rate (CAGR), from -$852.82M to $313.75M.
- What does net income mean?
- The total profit a company earns after all expenses and taxes are paid.